Hirsutism
3
Pipeline Programs
2
Companies
2
Clinical Trials
2
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
3
Early DiscoveryClinical DevelopmentMarket
On Market (2)
Approved therapies currently available
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AbbVieEflornithine hydrochloride
BayerDUS on the Prescribing Indications for CPA/EE in 5 European Countries
Clinical Trials (2)
Total enrollment: 1,675 patients across 2 trials
Evaluation of Eflornithine on Facial and Forearm Skin
Start: Nov 2004Est. completion: Oct 200578 patients
Phase 4Completed
DUS on the Prescribing Indications for CPA/EE in 5 European Countries
Start: Mar 2015Est. completion: Oct 20161,597 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.